Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01399372 · ClinicalTrials.gov registry record · Phase 2
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
NCT01399372 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 91 participants.
The verdict
NCT01399372, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, vincristine sulfate, procarbazine hydrochloride, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill cancer cells. It is not yet know whether rituximab and combination chemotherapy are more effective when given with or without radiation therapy in treating patients with primary central nervous system lymphoma. PURPOSE: This randomized phase II trial studies how well giving rituximab and combination chemotherapy with or without radiation therapy works in treating patients with primary central nervous system lymphoma.
Interventions
- DRUG Vincristine
- BIOLOGICAL Rituximab
- DRUG Cytarabine
- DRUG Methotrexate
- DRUG Procarbazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2011-09 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01399372
The ClinicalTrials.gov registry entry for NCT01399372 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Vincristine is the first listed.
NCT01399372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01399372 about?
NCT01399372 is a clinical study titled "Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma". RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate...
What is the current status of trial NCT01399372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2011-09. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT01399372?
The interventions under investigation include: Vincristine (DRUG), Rituximab (BIOLOGICAL), Cytarabine (DRUG), Methotrexate (DRUG), Procarbazine (DRUG).
Who is sponsoring clinical trial NCT01399372?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.